{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:56:54Z","timestamp":1775869014781,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40744-021-00332-w","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T18:03:16Z","timestamp":1624903396000},"page":"1435-1441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials"],"prefix":"10.1007","volume":"8","author":[{"given":"Carlo","family":"Salvarani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Dieude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Deberdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Rogai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Inciarte-Mundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"issue":"12","key":"332_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11926-017-0701-5","volume":"19","author":"Y Brito","year":"2017","unstructured":"Brito Y, Glassberg MK, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease: current concepts. Curr Rheumatol Rep. 2017;19(12):79.","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"332_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/ard.56.10.596","volume":"56","author":"B Cortet","year":"1997","unstructured":"Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high-resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(10):596\u2013600.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"332_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/ard.62.8.722","volume":"62","author":"C Turesson","year":"2003","unstructured":"Turesson C, O\u2019Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"332_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","volume":"49","author":"G Koduri","year":"2010","unstructured":"Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49(8):1483\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"332_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.21806","volume":"54","author":"S Suissa","year":"2006","unstructured":"Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1435\u20139.","journal-title":"Arthritis Rheum"},{"issue":"17","key":"332_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","volume":"11","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015;11(17):319.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"332_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","volume":"59","author":"C Vadillo","year":"2020","unstructured":"Vadillo C, Nieto MA, Romero-Bueno F, Leon L, Sanchez-Pernaute O, Rodriguez-Nieto MJ, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford). 2020;59(8):2099\u2013108.","journal-title":"Rheumatology (Oxford)"},{"key":"332_CR8","doi-asserted-by":"publisher","first-page":"6652845","DOI":"10.1155\/2021\/6652845","volume":"2021","author":"C Vacchi","year":"2021","unstructured":"Vacchi C, Manfredi A, Cassone G, Cerri S, Della Casa G, Andrisani D, et al. Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis. Case Rep Med. 2021;2021:6652845.","journal-title":"Case Rep Med"},{"issue":"1","key":"332_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","volume":"48","author":"C Fernandez-Diaz","year":"2018","unstructured":"Fernandez-Diaz C, Loricera J, Castaneda S, Lopez-Mejias R, Ojeda-Garcia C, Olive A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48(1):22\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"332_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.2147\/DDDT.S204730","volume":"13","author":"Y Huang","year":"2019","unstructured":"Huang Y, Lin W, Chen Z, Wang Y, Huang Y, Tu SJD, et al. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? Drug Des Dev Ther. 2019;13:2111.","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"332_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.122.3.1093","volume":"122","author":"R Vassallo","year":"2002","unstructured":"Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122(3):1093\u20136.","journal-title":"Chest"},{"issue":"5","key":"332_CR12","doi-asserted-by":"publisher","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","volume":"9","author":"P Kiely","year":"2019","unstructured":"Kiely P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):e028466.","journal-title":"BMJ Open"},{"key":"332_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang F, Sun L, Wang S, Davis JM III, Matteson EL, Murad MH, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95:1404\u201319.","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"332_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506\u201317.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"332_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"13","key":"332_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"332_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"332_CR18","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Smolen JS, Takeuchi T, Burmester G, Brinker D, Rooney TP, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):e347\u201357.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"332_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/annrheumdis-2018-214261","volume":"78","author":"B Combe","year":"2019","unstructured":"Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, et al. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019;78(8):1135\u20138.","journal-title":"Ann Rheum Dis"},{"key":"332_CR20","doi-asserted-by":"publisher","first-page":"106748","DOI":"10.1016\/j.intimp.2020.106748","volume":"86","author":"M d'Alessandro","year":"2020","unstructured":"d\u2019Alessandro M, Perillo F, MetellaRefini R, Bergantini L, Bellisai F, Selvi E, et al. Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. Int Immunopharmacol. 2020;86:106748.","journal-title":"Int Immunopharmacol"},{"key":"332_CR21","doi-asserted-by":"crossref","unstructured":"Citera G, Mysler E, Madariaga H, Cardiel MH, Casta\u00f1eda O, Fischer A, et al. Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2020.","DOI":"10.1097\/RHU.0000000000001552"},{"issue":"10","key":"332_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, Lindsey S, Takeuchi T, Fleischmann R, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1290\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00332-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00332-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T08:14:31Z","timestamp":1629620071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00332-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00332-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}